Persantin

Quick links to important sections

Persantin

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Persantin

Property Description
Active ingredient Dipyridamole (INN)
Form Coated tablet (Oral), Solution (IV)
Pharmacological class Platelet aggregation inhibitor, Coronary vasodilator
General purpose Supports blood flow and reduces clotting risk
Origin Synthetic

Dipyridamole: Definition and Pharmacological Classification

Persantin is a recognized trade name for the synthetic active substance Dipyridamole, which is primarily classified as both a Platelet aggregation inhibitor and a Coronary vasodilator. This classification relates to its ability to modulate blood elements and vessel tone. As a prescription-only product, Dipyridamole is characterized by its role in reducing the stickiness of blood cells. The medication's differentiation lies in its dual mechanism, which distinguishes it from single-pathway antiplatelet agents.

The Dual Purpose of Dipyridamole

The core objective of Dipyridamole is to support efficient circulation by initiating a dual physiological response. It works by making the blood platelets less prone to aggregate while simultaneously promoting the widening of specific arteries, particularly those supplying the heart. This action is the foundation for its use in settings where reduced blood flow and thrombosis risk are key concerns. The compound modulates cardiovascular dynamics, acting both on blood cells and the vascular wall. Therefore, the medication generally benefits the patient by ensuring blood flows more efficiently.

Pharmaceutical Preparations

Dipyridamole is supplied for systemic administration in two primary forms: the oral dosage form, typically presented as a coated tablet, and an injectable solution, which is a liquid intended for intravenous (IV) administration. This dual availability is a key distinguishing factor, permitting its use in chronic therapy as well as acute settings. While Persantin is a single-ingredient product, Dipyridamole also forms part of the combination product Aggrenox, underscoring its versatility within the anti-thrombotic regimen.

Regulatory References

  1. MedlinePlus NIH Source

What side effects are possible with Persantin?

Persantin, containing the active ingredient dipyridamole, is generally well-tolerated, but like all medicines, it can cause side effects. These effects often relate to the medicine's vasodilating (blood vessel widening) properties.

Common Side Effects

The most frequently reported side effects include:

  • Headache
  • Dizziness or lightheadedness, which may be more noticeable when getting up from a sitting or lying position.
  • Gastrointestinal issues, such as diarrhea, nausea, vomiting, or stomach cramps.
  • Flushing (a feeling of warmth or redness under the skin).

If these symptoms persist or become bothersome, discuss them with a healthcare professional.

Serious Side Effects and Safety Concerns

While rare, Persantin may cause serious adverse effects. Seek immediate medical attention if you experience:

  • Signs of a serious allergic reaction: Hives, difficulty breathing, or swelling of the face, lips, tongue, or throat (angioedema).
  • Chest pain or worsening of existing chest pain (angina pectoris), which can be a particular concern for individuals with pre-existing severe coronary artery disease.
  • Signs of liver problems: Yellowing of the skin or eyes (jaundice), dark urine, or unusual tiredness.
  • Unusual bleeding or bruising.

Contraindications

Persantin should not be used in individuals with a known allergy to dipyridamole. It should be used with caution in patients with severe coronary artery disease (such as unstable angina or recent myocardial infarction), low blood pressure (hypotension), and certain other heart conditions, as the vasodilating effect may aggravate these conditions. Patients with myasthenia gravis may require a dosage adjustment of their medication for that condition.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Dipyridamole is characterized by an exaggerated effect on the cardiovascular system and the presence of specific physical symptoms as documented in regulatory labeling. Officially documented clinical manifestations of an overdose include a warm feeling, flushes, sweating, restlessness, feeling of weakness, dizziness, and anginal complaints. A severe drop in blood pressure (hypotension) and an accelerated pulse (tachycardia) may be observed, reflecting the high-risk hemodynamic effects of the overdose. Chest pain may be aggravated or precipitated in individuals with underlying ischemic heart disease.

In the event of a real or suspected overdose, patients are mandated to seek immediate medical attention or contact a Poison Control Center immediately. Careful medical management is considered essential by regulatory authorities.

Management procedures officially described in the labeling include the recommendation of symptomatic treatment, with a vasopressor drug possibly being used to manage severe hypotension. Gastric lavage should be considered as a supportive measure. Furthermore, the administration of xanthine derivatives, such as aminophylline, is officially noted as a treatment that may reverse the hemodynamic effects of the overdose. ECG monitoring is advised during this medical situation. Experience with documented overdose cases remains limited.

Therapeutic Uses of Persantin

What Persantin Treats: Main Uses and Benefits

This medication is commonly used in clinical situations involving heightened systemic burden, specifically for managing the risk of serious blood clot formation (thromboembolism) in certain high-risk cardiovascular patients. The oral form is utilized as long-term support in situations involving heightened physiological stress, and is considered relevant for managing the risk of postoperative thromboembolic complications after cardiac valve replacement. It is also considered relevant for secondary prevention following an ischemic stroke or transient ischemic attack (TIA) when symptoms cluster into patterns requiring supportive management. The key benefit is supportive relief that helps ease the overall symptom burden and may assist with maintaining functional stability during symptomatic periods, which is relevant for the prevention of recurrent cerebrovascular events.

The injectable form is applied in settings where patients experience symptoms related to physical discomfort that interfere with daily functioning, to help manage conditions marked by increased physiological stress for diagnostic purposes. This medication is used in situations requiring short-term symptomatic assistance for the specialized evaluation of heart function, which is relevant for easing symptoms that create noticeable physiological strain.

“The medication provides supportive relief that helps ease the overall symptom burden and may assist with maintaining functional stability.”

Quick Fact: Relief for Thromboembolic Risk

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Persantin — official regulatory information

Eligibility scope Regulatory Stipulation
Populations for whom use is allowed (as stated in label): Adults, including the Elderly, for approved indications (e.g., as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement).
Populations for whom use is not recommended (if applicable): The Pediatric Population below the age of 12 years. Use during Pregnancy or Lactation requires caution and should occur only if clearly needed.
Populations for whom use is contraindicated: Patients with known hypersensitivity to dipyridamole or any component of the formulation.
Age-related eligibility rules: Safety and effectiveness are not established in the pediatric population below age 12. No specific dosage adjustment is required for the elderly.
Condition-specific eligibility rules: Use with caution in patients with severe coronary artery disease (e.g., unstable angina or recent myocardial infarction) and in those with hypotension. Caution is also required in cases of hepatic insufficiency.
Eligibility-related restrictions: Conditional use restrictions may apply to patients with Myasthenia Gravis and require temporary interruption prior to stress testing with certain adenosinergic agents.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use Persantin by establishing absolute prohibitions based on hypersensitivity, detailing specific cardiovascular conditions that necessitate conditional use with caution, and setting clear age-related boundaries where safety has not been documented. These rules delineate the regulatory scope of the eligible patient population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Dipyridamole (Persantin) documents interactions related to pharmacodynamic effects and effects on drug exposure.

Category Official Regulatory Statement
Contraindicated Combinations Co-administration with Riociguat is formally classified as contraindicated due to the documented risk of severe, additive hypotension. The combination with Abrocitinib is also restricted.
Pharmacodynamic Interactions A documented interaction exists with Anticoagulants (such as Warfarin) and Antiplatelet agents, which presents an additive anti-clotting effect and may increase the official classification risk for bleeding.
Exposure-Modifying Interactions Dipyridamole officially increases the plasma levels and cardiovascular effects of Adenosine and other adenosinergic agents by inhibiting their metabolism. Dipyridamole is also documented to counteract the effect of Cholinesterase Inhibitors, a pharmacodynamic interaction noted for patients with Myasthenia Gravis.
Transporter-Mediated Interactions The drug is documented to act as an inhibitor of the P-glycoprotein (P-gp) efflux transporter, which may alter the systemic exposure of co-administered medicines that are P-gp substrates.
Timing-based Administration Rule For patients who require pharmacological stress testing with intravenous Dipyridamole or other adenosinergic agents, the oral Dipyridamole tablets must be interrupted for 48 hours prior to testing. This procedural constraint prevents increased cardiovascular side effects and impaired test sensitivity.

Mechanism of Action

The mechanism of action of Dipyridamole is defined by two primary biological interactions. First, Dipyridamole acts as an inhibitor of Phosphodiesterase (PDE) enzymes within platelets, which blocks the hydrolysis of the intracellular messenger cyclic AMP (cAMP). The resulting elevation of cAMP acts as an internal signal to suppress the platelet activation cascade and subsequent aggregation. Second, the molecule blocks the Equilibrative Nucleoside Transporter 1 (ENT1) on cell surfaces, which prevents the reuptake of extracellular adenosine. This inhibition sustains elevated concentrations of adenosine outside the cells. This enhanced adenosine signaling potentiates the relaxation of vascular smooth muscle by activating A2 A receptors, which ultimately results in coronary vasodilation and hyperemia. This vasodilatory mechanism is subject to competitive antagonism, as substances like methylxanthines (e.g., caffeine) can directly interfere with the signaling pathway by binding to adenosine receptors.

Dosage and Administration Information

Persantin (dipyridamole) is administered via two primary routes: the oral route for long-term use and intravenous (IV) infusion for short-term diagnostic procedures.

Oral Administration

Oral dipyridamole is available as immediate-release tablets and prolonged-release capsules. The immediate-release tablets are typically administered at a dose of 75 mg to 100 mg four times daily (QID) when used as an adjunct to warfarin therapy. In contrast, prolonged-release capsules are usually administered twice daily (BID) and must be swallowed whole without chewing or crushing. Tablets and oral suspensions are often taken before meals, while the prolonged-release capsule is taken with or soon after a meal.

Intravenous (IV) Infusion

The injectable solution (5 mg/mL) is for IV use during specialized cardiac evaluations. The standard total dose for this diagnostic procedure is 0.56 mg/kg of body weight, administered at a rate of 0.142 mg/kg/minute over a fixed 4-minute period. Prior to infusion, the solution requires dilution in at least a 1:2 ratio with 0.9% sodium chloride or 5% dextrose injection to a total volume of approximately 20 to 50 mL. Patients receiving oral dipyridamole for chronic management must discontinue it 24 hours prior to receiving the IV infusion for stress testing.

For most prolonged-release formulations, no dosage adjustment is necessary for older adults or patients with renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Persantin

Evidence for Preventing Recurrent Stroke and TIA

Research examined the medicine’s role in exploring the chance of a subsequent event in adults who previously experienced an ischemic stroke or a transient ischemic attack (TIA). This area was evaluated in large-scale Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews.

Studies exploring the medicine in combination with aspirin were observed in studies where differences in event measurements were recorded compared to aspirin used alone. The most pronounced differences in observed patterns were noted in the trials that specifically examined an extended-release formulation of the medicine. Findings varied across studies that observed the medicine as a monotherapy for prevention.

What remains uncertain is the long-term observation of patient outcomes beyond the duration of the key clinical trials, which spanned approximately one to two years. Existing studies provide limited insight into the consistent comparative performance of the medicine when evaluated alone versus standard single antiplatelet therapy.


Evidence for Use with Mechanical Heart Valves

Research focused on outcomes for patients with prosthetic heart valves, examining the medicine as an adjunct alongside conventional oral anticoagulant therapy. Outcomes monitored included the incidence of thromboembolic events (clot formation) and overall mortality over time.

Trials structured to assess the addition of Dipyridamole to oral anticoagulant therapy reported different patterns in event measurements. The approach was also associated with observed differences in overall mortality measurements in the studied populations. The reported outcomes are specific to research where the medicine was evaluated as an adjunct to primary treatment.


Evidence for Diagnostic Evaluation of Heart Function (IV Form)

The intravenous form of the medicine was studied for use in a specific, acute diagnostic setting. This research was primarily conducted on adult populations who were not candidates for a standard exercise-based cardiac stress test. Studies consistently reported changes in coronary blood flow measurements immediately following the IV administration. Since the application is limited to a single diagnostic procedure, research has not examined therapeutic or long-term clinical outcomes in this context.

Key Studies & References

  1. Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves (Meta-analysis of the randomized trials)
  2. Dipyridamole Nuclear Stress Test (ASNC Practice Points / Clinical Guidelines)

Frequently Asked Questions (FAQ)

Common questions about Persantin (FAQ)

Q: How quickly should a person expect Persantin to start working?

According to pharmacological data, the antiplatelet effect of the oral form is typically observed within approximately two hours of consumption. The concentration of the medicine in the bloodstream usually reaches its highest point within 2 to 2.5 hours.

Q: What happens if I forget to take my Persantin?

Regulatory patient information describes that a missed dose may be taken as soon as it is recalled. However, if the timing is close to the next scheduled dose, the missed dose should be skipped entirely. Regulatory guidance states that two doses should never be taken together.

Q: Are there common skin reactions associated with Persantin?

Official regulatory labeling indicates that rash and hives (urticaria) are reported signs of a hypersensitivity reaction. Other skin-related effects, such as purple-colored spots or patches on the skin, have also been reported in patient populations.

Q: Can Persantin be taken with common pain relievers like ibuprofen?

Official patient guidance cautions against combining common non-steroidal anti-inflammatory painkillers, such as ibuprofen, with this medicine. The combination may increase the official classification risk for bleeding.

Q: Does Persantin interact with supplements or vitamins?

Regulatory patient information notes that some herbal remedies and supplements may interact with the medicine, particularly those that affect the blood, like ginkgo. Because of this potential, patients must disclose all supplements and remedies to a healthcare professional.

Q: Is it safe to drink coffee or tea while taking Persantin?

For the oral medicine used for long-term therapy, a clinically significant interaction with normal caffeine consumption is generally not expected. The major interaction between caffeine and this medicine is primarily a concern for the specialized intravenous stress test procedure.

Q: Does alcohol affect how Persantin works in the body?

While alcohol consumption is not formally forbidden, both alcohol and the medicine may lead to a reduction in blood pressure. Combining them can increase the potential for experiencing side effects such as dizziness or lightheadedness.

Q: What is the difference between Persantin and other antiplatelet drugs?

Official documents highlight that this medicine has a dual function that distinguishes it from other antiplatelet agents. Its mechanism works both to reduce platelet stickiness and to help widen certain blood vessels.

Q: Do I need to change my diet while using Persantin?

Regulatory guidance indicates that no general changes to a patient's diet are necessary while using this medicine. Guidance focuses mainly on the timing of the dose relative to meals and the moderation of alcohol consumption.

Q: How long does the effect of a single Persantin dose last?

The medicine's half-life dictates the length of its therapeutic presence in the body. For the intravenous form used in specialized diagnostic testing, the blood vessel widening effect can last for more than 50 minutes following administration.

Q: Does Persantin have long-term side effects that I should know about?

The medicine is generally considered suitable for long-term use and is often prescribed for extended periods. The official labeling lists common and serious adverse effects which are relevant throughout the course of treatment.

Q: Is Persantin generally considered safe for long-term use?

Yes, official patient guidance indicates that the medicine is generally considered suitable for long-term use. It is often prescribed for extended periods to fulfill its purpose in reducing the risk of blood clot formation.

Q: Has there been recent research on new uses for Persantin?

Studies and regulatory reviews indicate that research is ongoing to explore potential new applications for the medicine beyond its currently approved indications. These themes include its effects in areas like neuroprotection and its role in certain thrombotic complications.

Q: Is Persantin commonly used outside of the United States?

The medicine is widely used and approved in many countries globally. Its official regulatory approval status, availability, and brand name may differ across regions, as seen in official regulatory documents from various international health bodies.

Q: Can Persantin be taken by people with asthma or other breathing problems?

Regulatory caution is documented for patients who may experience bronchospasm, which is a narrowing of the airways. This necessity of discussing the full medical history is essential for patients with pre-existing breathing or pulmonary conditions.

Q: Are there documented cases of Persantin withdrawal if stopped suddenly?

Official guidance warns that stopping the medicine may lead to the blood's ability to clot returning to its previous state within approximately two days. This change may result in an increased risk of serious cardiovascular events.

Q: Is Persantin available as a generic medicine?

Yes, the active ingredient, dipyridamole, is available in generic formulations. This is due to the expiration of most of the original patent protections, as documented by regulatory and patent information.

Q: Are there any official recommendations about driving while taking Persantin?

Official patient information states that if the medicine causes dizziness, which is a commonly reported side effect, it is recommended not to drive or use tools or machinery until the effect has fully passed.

Q: Is Persantin the same kind of medicine as aspirin?

This medicine is classified as an antiplatelet agent, which is the same class as aspirin. However, they are distinct compounds that are sometimes used together in combination therapy to prevent blood clots. Official guidance states patients should not use over-the-counter high-dose aspirin for pain while taking this medicine.

Q: Is there a link between Persantin and changes in blood pressure?

Yes, the medicine is officially classified as a vasodilator, meaning it helps widen blood vessels. This action may be associated with a reduction in blood pressure, which can lead to common side effects like dizziness or lightheadedness.

Q: Is Persantin safe for older adults or seniors?

Official labeling indicates that this medicine is suitable for use in older adults, including the elderly, for its approved indications. No specific dosage adjustment is typically required for this population, and the medicine is generally considered suitable for long-term use.

Q: Why is Persantin sometimes given with warfarin or other anticoagulants?

The medicine is officially indicated for use as an adjunct (an additional treatment) alongside conventional oral anticoagulants like warfarin. This combination helps prevent blood clot formation in specific patient groups, such as those with mechanical heart valves.

Q: What should I do if a side effect seems to get worse after starting Persantin?

If a non-serious side effect becomes bothersome or worsens, consultation with a healthcare professional is necessary. Immediate emergency medical attention is required if any symptoms officially listed as serious side effects are experienced.

Q: Is Persantin ever used for people who have had a stroke?

Yes, regulatory labeling confirms that the medicine, often in combination with aspirin, is officially approved for the secondary prevention of stroke or transient ischemic attack (TIA). This is for patients who have previously experienced one of these events.

Q: Can Persantin be crushed or split?

Official patient information states that both the prolonged-release capsules and the immediate-release tablets are intended to be swallowed whole with a drink of water. Patients are explicitly instructed not to crush or chew the prolonged-release capsules.

Q: What information is available about Persantin use during pregnancy?

Regulatory labeling indicates that the medicine is officially not recommended for use during the third trimester of pregnancy. Its use during the first and second trimesters requires consultation with a healthcare professional to assess the potential need and benefit.

Q: Is it normal to feel a warming sensation after taking Persantin?

Yes, the official list of commonly reported side effects includes flushing. This is described in regulatory documents as a feeling of warmth or redness under the skin.

How should Persantin be stored and disposed of?

Official Storage and Disposal Requirements

Persantin (dipyridamole) must be stored at Room Temperature and should be maintained below 25 C (77 F), away from excess heat and moisture. To preserve stability, the medication must be kept in the container it came in and maintained tightly closed.

Storage Restriction Official Requirement
Temperature Store at Room Temperature / Below 25 C
Moisture Keep container tightly closed; store away from excess moisture
Child Safety Mandatory—Keep strictly out of the reach of children
Disposal Method Preferred: Utilize a drug take-back program.
Trash Preparation Mix with an undesirable substance before sealing and placing in household trash (if no take-back program is available).

The packaging must be secured with locked safety caps and placed in an elevated, secure location to fulfill the required child-safety constraints. Unused medicinal product or waste material must be disposed of in accordance with local environmental requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Persantin found in:

A-Z Index: